Develops therapies for neurological diseases. Focuses on immunoscience disease treatments. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 30 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $738.8M against $0 in annual sales.
This stock swings about 3.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, BHVN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BHVN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (17/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.